Literature DB >> 10731630

Effects of acute metabolic stress on striatal dopamine release in healthy volunteers.

C M Adler1, I Elman, N Weisenfeld, L Kestler, D Pickar, A Breier.   

Abstract

Several lines of evidence indicate that a variety of metabolic stressors, including acute glucose deprivation are associated with dopamine release. Pharmacologic doses of the glucose analogue, 2-deoxyglucose (2DG) cause acute glucoprivation and are associated with enhanced dopamine turnover in preclinical studies. In this study, we utilized [11C]raclopride PET to examine 2DG-induced striatal dopamine release in healthy volunteers. Six healthy volunteers underwent PET scans involving assessment of 2DG-induced (40 mg/kg) decrements in striatal binding of the D(2)/D(3) receptor radioligand [11C]raclopride. Decreases in [11C]raclopride specific binding reflect 2DG-induced changes in synaptic dopamine. Specific binding significantly decreased following 2DG administration, reflecting enhanced synaptic dopamine concentrations (p =.02). The administration of 2DG is associated with significant striatal dopamine release in healthy volunteers. Implications of these data for investigations of the role of stress in psychiatric disorders are discussed.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10731630     DOI: 10.1016/S0893-133X(99)00153-0

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  22 in total

Review 1.  Psychosocial stress and psychosis. A review of the neurobiological mechanisms and the evidence for gene-stress interaction.

Authors:  Ruud van Winkel; Nicholas C Stefanis; Inez Myin-Germeys
Journal:  Schizophr Bull       Date:  2008-08-20       Impact factor: 9.306

2.  Advances in PET analyses of stress and dopamine.

Authors:  Romina Mizrahi
Journal:  Neuropsychopharmacology       Date:  2010-01       Impact factor: 7.853

Review 3.  CRF modulation of central monoaminergic function: Implications for sex differences in alcohol drinking and anxiety.

Authors:  Kristen E Pleil; Mary Jane Skelly
Journal:  Alcohol       Date:  2018-02-02       Impact factor: 2.405

Review 4.  Preclinical evidence implicating corticotropin-releasing factor signaling in ethanol consumption and neuroadaptation.

Authors:  T J Phillips; C Reed; R Pastor
Journal:  Genes Brain Behav       Date:  2015-01       Impact factor: 3.449

5.  Hypothesizing dopaminergic genetic antecedents in schizophrenia and substance seeking behavior.

Authors:  Kenneth Blum; Marlene Oscar-Berman; Rajendra D Badgaiyan; Tomas Palomo; Mark S Gold
Journal:  Med Hypotheses       Date:  2014-02-26       Impact factor: 1.538

6.  Differential effects of acute stress on anticipatory and consummatory phases of reward processing.

Authors:  P Kumar; L H Berghorst; L D Nickerson; S J Dutra; F K Goer; D N Greve; D A Pizzagalli
Journal:  Neuroscience       Date:  2014-02-07       Impact factor: 3.590

Review 7.  Neurogenetics of dopaminergic receptor supersensitivity in activation of brain reward circuitry and relapse: proposing "deprivation-amplification relapse therapy" (DART).

Authors:  Kenneth Blum; Thomas J H Chen; B William Downs; Abdalla Bowirrat; Roger L Waite; Eric R Braverman; Margaret Madigan; Marlene Oscar-Berman; Nicholas DiNubile; Eric Stice; John Giordano; Siobhan Morse; Mark Gold
Journal:  Postgrad Med       Date:  2009-11       Impact factor: 3.840

8.  Association of diabetes with dyskinesia in older psychosis patients.

Authors:  Michael P Caligiuri; Dilip V Jeste
Journal:  Psychopharmacology (Berl)       Date:  2004-05-12       Impact factor: 4.530

Review 9.  Pathway-Specific Dopamine Abnormalities in Schizophrenia.

Authors:  Jodi J Weinstein; Muhammad O Chohan; Mark Slifstein; Lawrence S Kegeles; Holly Moore; Anissa Abi-Dargham
Journal:  Biol Psychiatry       Date:  2016-03-31       Impact factor: 13.382

10.  Food reinforcement, the dopamine D2 receptor genotype, and energy intake in obese and nonobese humans.

Authors:  Leonard H Epstein; Jennifer L Temple; Brad J Neaderhiser; Robbert J Salis; Richard W Erbe; John J Leddy
Journal:  Behav Neurosci       Date:  2007-10       Impact factor: 1.912

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.